Prediagnostic Serum Immune Marker Levels and Multiple Myeloma: A Prospective Longitudinal Study Using Samples from the Janus Serum Bank in Norway
This study observed a decline in TGF-α serum levels closer to multiple myeloma diagnosis, which may aid in predicting multiple myeloma progression and early detection, although validation in other longitudinal cohorts is needed.
Authors
- Carl Wibom (ORCID: https://orcid.org/0000-0001-8851-2905)
- Roel C.H. Vermeulen (ORCID: https://orcid.org/0000-0003-4082-8163)
- Florentin Späth (ORCID: https://orcid.org/0000-0002-0711-0830)
- Wendy Wu (ORCID: https://orcid.org/0000-0002-6169-5155)
- Hilde Langseth (ORCID: https://orcid.org/0000-0002-9446-4855)
- Esmeralda Krop (ORCID: https://orcid.org/0000-0002-6009-1181)
- Sophia Harlid (ORCID: https://orcid.org/0000-0001-8540-6891)
- Simona Herdenberg (ORCID: https://orcid.org/0009-0003-2593-6470)
Institutions
- Utrecht University (NL)
- Cancer Registry of Norway (NO)
- South Australian Health and Medical Research Institute (AU)
- Imperial College London (GB)
- The University of Adelaide (AU)
- Umeå University (SE)
Publication Details
- Journal
- Cancer Prevention Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1158/1940-6207.capr-24-0501
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancerfonden
- Svenska Sällskapet för Medicinsk Forskning
- Umeå Universitet
- Cancer Research Foundation in Northern Sweden
- Kempestiftelserna
- Svenska Läkaresällskapet